Context Therapeutics Inc.
NASDAQ:CNTXBiotechnology
Healthcare
$0.69 +2.93%
+$0.02 today
- Market cap
- $63.67M
- Beta
- 1.61
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.42
52W Low $0.56High $3.62
Volume 1.71M
Average 1.16M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$39.70M
FY 2025 · Annual
Net Income
-$36.12M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 3.81M | 7.09M | 17.78M | 22.7M | 31.86M |
| Selling, General & Admin | 3.63M | 7.79M | 7.29M | 7.22M | 7.85M |
| Operating Expenses | 10.53M | 15.38M | 25.07M | 29.92M | 39.7M |
| Depreciation & Amortization | 0 | 9.27K | 12.04K | 10.88K | 16.25K |
| EBITDA | (7.44M) | (14.87M) | (23.95M) | (26.71M) | (36.11M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (10.53M) | (15.38M) | (25.07M) | (29.92M) | (39.7M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 64 | 547.27K | 1.16M | 3.2M | 3.38M |
| Interest Expense | 64.24K | 547.27K | 0 | 0 | 0 |
| Other Income / Expenses | 68.95K | 545.26K | 1.11M | 3.2M | 3.58M |
| Income Before Tax | (10.46M) | (14.84M) | (23.96M) | (26.73M) | (36.12M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (10.46M) | (14.84M) | (23.96M) | (26.73M) | (36.12M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (3.69) | (0.93) | (1.50) | (0.46) | (0.38) |
| EPS (Diluted) | (3.69) | (0.93) | (1.50) | (0.46) | (0.38) |
| 2.83M | 15.97M | 15.97M | 58.42M | 95.19M | |
| 2.83M | 15.97M | 15.97M | 58.42M | 95.19M |
CNTX Earnings Waterfall · TTM
NASDAQ:CNTX · Revenue to Net Income
Key Ratios
EPS$-0.42
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-3.5
P/S Ratio0.0
Analysis
$0 of revenue converted into -$40.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.42, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Jun 26, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 26, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 26, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 26, 2026 | |
| 8-K | Current report | Jun 26, 2026 |
How much revenue does CNTX generate?
Context Therapeutics Inc. (CNTX) reported $0.00 of revenue in fiscal 2025.
Is CNTX profitable?
Context Therapeutics Inc. (CNTX) reported -$36.12M of net income.
Continue the stock analysis
Jump to another research area for this company.